Tenaya Therapeutics Inc. has announced the presentation of interim data from its ongoing MyClimb™ natural history study at the European Society of Cardiology Congress 2025. The study focuses on pediatric participants with MYBPC3-associated hypertrophic cardiomyopathy $(HCM)$, marking it as the largest noninterventional natural history study of individuals under 18 with this condition. The interim findings reveal that 93% of participants have the nonobstructive form of HCM, for which there are currently no approved therapeutics. Key observations from the study indicate that genotypic status is a significant predictor of risk, and a higher left ventricular mass index may serve as a surrogate marker for poor long-term outcomes. These insights could influence future risk stratification and intervention strategies, as well as inform clinical trial endpoints and eligibility criteria for potential genetic treatments like TN-201 gene therapy.